Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
Contenu
Click for External Resource*
Click to read full article*
*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.
Item Type
PublicationTerms of Use
By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.
Titre
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
Sujet
Description
There is significant international interest in heterologous prime-boost COVID-19 vaccination to mitigate against supply shocks or shortages that might otherwise reduce the speed of vaccine roll-out. Additionally, in light of changing recommendations regarding use of the ChAdOx1 nCoV-19 (ChAd) COVID-19 vaccine (Vaxzevria, AstraZeneca), several countries are now advising that individuals previously primed with this vaccine should now receive an alternative vaccine as their second dose, most commonly mRNA vaccines such as the BNT162b2 (BNT) COVID-19 vaccine (Comirnaty, Pfizer-BioNTech), administered in a heterologous prime-boost schedule.
Date
2021-05-12
Type
Citer ce document
Shaw, Robert H., Arabella Stuart, Melanie Greenland, Xinxue Liu, Jonathan S. Nguyen Van-Tam, and Matthew D. Snape. 2021. "Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data." The Lancet.
Accessibilité
Free online on Lancet site.
Was this resource helpful?